Artiva Biotherapeutics, Inc.
ARTV
$2.47
$0.020.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 251.00K | 2.60M | 29.26M | 32.75M | 33.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 251.00K | 2.60M | 29.26M | 32.75M | 33.49M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 251.00K | 2.60M | 29.26M | 32.75M | 33.49M |
| SG&A Expenses | 17.21M | 15.42M | 13.39M | 13.59M | 13.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 67.54M | 63.59M | 61.10M | 60.23M | 64.16M |
| Operating Income | -67.28M | -60.99M | -31.84M | -27.48M | -30.67M |
| Income Before Tax | -65.37M | -61.20M | -32.45M | -25.89M | -28.65M |
| Income Tax Expenses | -- | 72.00K | 72.00K | 72.00K | 72.00K |
| Earnings from Continuing Operations | -65.37 | -61.28 | -32.53 | -25.97 | -28.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.37M | -61.28M | -32.53M | -25.97M | -28.72M |
| EBIT | -67.28M | -60.99M | -31.84M | -27.48M | -30.67M |
| EBITDA | -64.85M | -58.58M | -29.50M | -25.20M | -28.41M |
| EPS Basic | -40.82 | -54.99 | -40.08 | -32.17 | -35.99 |
| Normalized Basic EPS | -25.99 | -43.87 | -34.56 | -29.62 | -32.00 |
| EPS Diluted | -41.48 | -69.81 | -67.27 | -59.36 | -63.18 |
| Normalized Diluted EPS | -25.99 | -43.87 | -42.28 | -37.34 | -39.73 |
| Average Basic Shares Outstanding | 44.90M | 21.33M | 3.24M | 3.23M | 3.21M |
| Average Diluted Shares Outstanding | 44.90M | 21.33M | 9.40M | 9.39M | 9.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |